DRUG Key Statistics, Chart & Performance
The current stock price of DRUG is 76.19 USD. In the past month the price decreased by -4.77%. In the past year, price increased by 73.32%.
DRUG Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to DRUG. When comparing the yearly performance of all stocks, DRUG is one of the better performing stocks in the market, outperforming 92.57% of all stocks.
DRUG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRUG. The financial health of DRUG is average, but there are quite some concerns on its profitability.
DRUG Financial Highlights
Over the last trailing twelve months DRUG reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -152.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.49% | ||
| ROE | -14.91% | ||
| Debt/Equity | 0 |
DRUG Forecast & Estimates
DRUG Ownership
DRUG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.54 | 398.827B | ||
| AMGN | AMGEN INC | 15.03 | 182.324B | ||
| GILD | GILEAD SCIENCES INC | 16.04 | 177.765B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.87 | 118.135B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 79.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.12 | 46.476B | ||
| INSM | INSMED INC | N/A | 33.518B | ||
| NTRA | NATERA INC | N/A | 31.422B | ||
| BIIB | BIOGEN INC | 11.44 | 25.931B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.23 | 20.594B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRUG
Company Profile
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Company Info
BRIGHT MINDS BIOSCIENCES INC
19 Vestry Street
New York City NEW YORK US
Employees: 0
Phone: 16478658622
BRIGHT MINDS BIOSCIENCES INC / DRUG FAQ
What does BRIGHT MINDS BIOSCIENCES INC do?
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
What is the stock price of BRIGHT MINDS BIOSCIENCES INC today?
The current stock price of DRUG is 76.19 USD. The price decreased by -3.12% in the last trading session.
Does BRIGHT MINDS BIOSCIENCES INC pay dividends?
DRUG does not pay a dividend.
What is the ChartMill rating of BRIGHT MINDS BIOSCIENCES INC stock?
DRUG has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for BRIGHT MINDS BIOSCIENCES INC?
BRIGHT MINDS BIOSCIENCES INC (DRUG) operates in the Health Care sector and the Biotechnology industry.
How many employees does BRIGHT MINDS BIOSCIENCES INC have?
BRIGHT MINDS BIOSCIENCES INC (DRUG) currently has 0 employees.
What is BRIGHT MINDS BIOSCIENCES INC worth?
BRIGHT MINDS BIOSCIENCES INC (DRUG) has a market capitalization of 593.52M USD. This makes DRUG a Small Cap stock.